Targeting prostaglandin D2 (PGD2) metabolism confers protection against radiotherapy-induced esophageal toxicity
Journal of Pharmaceutical Analysis · 2026-11 · 101843
DOI: 10.1016/j.jpha.2026.101843 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-11. Verfasst von Hangfeng Liu und 12 weiteren Autor:innen. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, H., Lin, H., Jiang, S., Zhang, J., Wang, P., Zhou, B., Li, Q., Song, B., Yang, Z., Zhang, S., Ying, X., Feng, T., & Tu, W. (2026). Targeting prostaglandin D2 (PGD2) metabolism confers protection against radiotherapy-induced esophageal toxicity. Journal of Pharmaceutical Analysis, 101843. https://doi.org/10.1016/j.jpha.2026.101843
Vancouver
Liu H, Lin H, Jiang S, Zhang J, Wang P, Zhou B, et al. Targeting prostaglandin D2 (PGD2) metabolism confers protection against radiotherapy-induced esophageal toxicity. Journal of Pharmaceutical Analysis. 2026:101843. doi:10.1016/j.jpha.2026.101843
BibTeX
@article{Liu2026,
author = {Liu, Hangfeng and Lin, Hongyu and Jiang, Sheng and Zhang, Jinkang and Wang, Ping and Zhou, Bo and Li, Qing and Song, Bin and Yang, Zhenguo and Zhang, Shuyu and Ying, Xue and Feng, Tang and Tu, Wenling},
title = {Targeting prostaglandin D2 (PGD2) metabolism confers protection against radiotherapy-induced esophageal toxicity},
journal = {Journal of Pharmaceutical Analysis},
year = {2026},
pages = {101843},
doi = {10.1016/j.jpha.2026.101843}
}
EUVIMED